MannKind | MNKD - Ebit


MannKind reported $-41.05M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Adma Biologics USD 49.19M 7.26M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Insmed USD -261.35M 7.48M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Merck USD 7.56B 1.19B Sep/2025
Novo Nordisk DKK 5.18B 37.04B Jun/2025
Pfizer USD 4.57B 1.97B Sep/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Xencor USD -47.52M 24.69M Sep/2025